CopyMark Law Group
4.9/5
Drawing for AITEM

USPTO serial 79350047

AITEM

Reviewed by CopyMark Law Group

Reg. 7369448Status 700Registered
Filing date
Status date
Registration date
Apr 30, 2024
Examiner
MATZINGER, AMY L
Law office
FILE REPOSITORY (FRANCONIA)

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with AITEM?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Trademark Monitoring
(312) 319-4460
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Start a new application
(312) 319-4460

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

MARK E. BANDY

MARK E. BANDY Rankin Hill & Clark, LLP38210 Glenn AvenueWilloughby, OH 44094UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Medicines for human purposes, namely, for use for central nervous system diseases, liver diseases, lung diseases, cancers, immune system diseases, infectious diseases, kidney and gastrointestinal diseases; Pharmaceutical preparations, namely, for use for central nervous system medications, liver disease medications, lung disease medications, anti-tumor medications, immune system medications, anti-infective medications, kidney disease medications, and gastrointestinal medications; Chemico-pharmaceutical preparations, namely, for use for central nervous system medications, liver disease medications, lung disease medications, anti-tumor medications, immune system medications, anti-infective medications, kidney disease medications, and gastrointestinal medications; Capsules being medicines, namely, capsules for the treatment of central nervous system diseases, liver diseases, lung diseases, cancers, immune system diseases, infectious diseases, kidney related diseases, gastrointestinal diseases; Sedatives; Vaccines; Drugs for medical purposes, namely, central nervous system medications, liver disease medications, lung disease medications, anti-tumor medications, immune system medications, anti-infective medications, kidney disease medications, and gastrointestinal medications; Medicines in tablet form, namely, medicinal preparations for the mouth to be applied in the form of tablets; Injectable medicinal solutions, namely, powder for injection, parenteral solutions, solutions for injection, intravenous injections, suspensions for injection, sterile powders for injection, intravenous injections, emulsion for injection, emulsion injections, powder injections, and concentrated solutions for injection, all for the treatment of central nervous system diseases, liver diseases, lung diseases, cancers, immune system diseases, infectious diseases, kidney and gastrointestinal diseases; Pain relief medication; Immunostimulants; Pharmaceuticals for the treatment of cancer; Pharmaceuticals for the treatment of infectious diseases; Pharmaceuticals for the treatment of viral diseases; Medicinal preparations for the treatment of musculoskeletal disorders; Drugs and preparations for the treatment of gastrointestinal diseases; Medicinal preparations for skin diseasesACTIVE—
042Design of computer databases; Conversion of computer programs and data, other than physical conversion; Digitization of documents being scanning; Computer programming in medical care; Providing virtual computer systems through cloud computing; Pharmaceutical drug development; Drug evaluation in the nature of evaluation and testing of illegal clandestine drug lab sites for the presence of hazardous and illegal materials; Pharmaceutical research; Scientific research and development; Conducting early evaluation of new drug fields in the nature of evaluation and testing of illegal clandestine drug lab sites for the presence of hazardous and illegal materials; Computer hardware design; Research and development of new products for others; Providing computer software design for others; Electronic data storage; Conducting technical project studies in the nature of technical research in the field of pharmaceutical studies; Conversion of data or documents from physical to electronic media; Clinical trials, namely, scientific research in the nature of conducting clinical trials for others; Animal genetics research in the nature of studying the mechanism of action of compound combinations in animals; Computer programmingACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jul 23, 2026CHLDCHANGE OF OWNER RECEIVED FROM IB—
Dec 7, 2024FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Oct 27, 2024XXSSGENERIC MADRID TRANSACTION SENT TO IB—
Oct 26, 2024XXCRGENERIC MADRID TRANSACTION CREATED—
Jul 30, 2024FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Apr 30, 2024NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Apr 30, 2024NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Apr 30, 2024R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Mar 17, 2024OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
Feb 26, 2024OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Feb 21, 2024OPNRNOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB—
Feb 19, 2024GPNXNOTIFICATION PROCESSED BY IB—
Feb 13, 2024NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Feb 13, 2024PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jan 29, 2024OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Jan 24, 2024OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Jan 24, 2024NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jan 10, 2024CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jan 4, 2024XAECEXAMINER'S AMENDMENT ENTERED—
Jan 4, 2024GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Jan 4, 2024GNEAEXAMINERS AMENDMENT E-MAILED—
Jan 4, 2024CNEAEXAMINERS AMENDMENT -WRITTEN—
Dec 8, 2023TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Dec 8, 2023CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Dec 8, 2023TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Nov 19, 2023DOCKASSIGNED TO EXAMINER—
Jul 22, 2023RFNPREFUSAL PROCESSED BY IB—
Jun 23, 2023RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Jun 22, 2023RFRRREFUSAL PROCESSED BY MPU—
May 18, 2023RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
May 17, 2023CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 2, 2023DOCKASSIGNED TO EXAMINER—
Sep 24, 2022MAFRAPPLICATION FILING RECEIPT MAILED—
Sep 20, 2022NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Sep 16, 2022REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance